Physician profile
Stephen J Bernstein
NPI 1215017736
$208,111.01
in general payments reported to CMS, 2019-2025
49 companies · $35K in 2025
The $35K reported for 2025 was more than what 95% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51K · 2020: $18K · 2021: $12K · 2022: $28K · 2023: $27K · 2024: $36K · 2025: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $80K · Food and Beverage: $14K · Travel and Lodging: $3,471 · Gift: $40.59 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $80,317.50 |
| Food and Beverage | $14,009.31 |
| Travel and Lodging | $3,470.91 |
| Gift | $40.59 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $106,992.69 | 2019-2025 | Rinvoq, Skyrizi, Synthroid |
| Mallinckrodt Hospital Products INC. | $46,273.91 | 2020-2025 | Acthar |
| Mallinckrodt Enterprises LLC | $31,394.88 | 2019 | |
| Amgen INC. | $3,391.12 | 2019-2025 | Otezla, Enbrel, Tavneos |
| Eli Lilly and Company | $2,475.00 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $2,025.61 | 2019-2025 | Breztri, Saphnelo, Airsupra |
| Novo Nordisk INC | $1,940.93 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $1,720.73 | 2019-2025 | |
| Lilly USA, LLC | $1,258.85 | 2019-2025 | Taltz |
| Glaxosmithkline, LLC. | $1,246.53 | 2019-2025 | Benlysta, Trelegy Ellipta, Shingrix |
| Ucb, INC. | $1,239.91 | 2019-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $918.67 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $780.24 | 2019-2020 | |
| Ibsa Pharma INC. | $750.00 | 2020 | |
| Janssen Biotech, INC. | $570.63 | 2019-2025 | Tremfya |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Bernstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.